HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a "1+2+3+4=1" service system and can supply alpha lipoic acid sourced directly from multiple well-known original manufacturers.
As a foreign trade enterprise with R&D capabilities, HiSiaddi has repeatedly proposed alpha-lipoic acid formulation optimization schemes and application improvement suggestions through technological cooperation with manufacturers and precise market insight. Below is a technical consulting case of alpha-lipoic acid formulation optimization delivered by HiSiaddi.
Contact HiSiaddi customer service for inquiries about formulation optimization consulting services.
The buyer is FRANCE NUTRILAB, a premium French nutritional pharmaceutical group headquartered in Lyon, France. With 27 years of expertise in high-end medical dietary supplements, oral anti-aging soft capsules and clinical anti-aging essence stock solutions across France, Switzerland and Belgium, its products are sold in premium private clinics in Paris, high-end pharmacy chains in France and Switzerland, and organic European supermarket counters. Raw materials comply with European EP Pharmacopoeia, EFSA food additive specifications, REACH chemical regulations and France’s AFNOR domestic raw material control standards. Its three flagship finished products include medical dietary soft capsules for diabetic peripheral nerve repair, anti-glycation sustained-release hard oral capsules and weakly acidic antioxidant clinical essences, targeting middle and high-net-worth consumers in Western Europe. The group maintains stable annual alpha-lipoic acid procurement of 21 tons, historically sourcing pharmacopoeia-grade alpha-lipoic acid from Roche (Switzerland).
Driven by continuous price hikes of local European chemical raw materials, high minimum customized order thresholds of 4 tons from original manufacturers and extended sea freight cycles of up to 80 days, the group launched a domestic raw material substitution project in 2025. It sourced an initial batch of 3.6 tons of national standard DL-alpha-lipoic acid from three leading domestic alpha-lipoic acid manufacturers, yet five major mass production failures emerged immediately after raw material delivery and production launch: persistent soft capsule filling clogging, rapid oxidative discoloration of finished goods during storage, layer separation and precipitation in essence compounding, sulfur odor overflow during production, and excessive active ingredient attenuation incompatible with formulations. Multiple fully automatic German production lines were forced to intermittent shutdowns, resulting in semi-finished product scrapping losses exceeding 50,000 Euros.
Domestic raw material manufacturers only mastered raw material synthesis and production, lacking knowledge of end-product formulation logic and European production line process characteristics, and could not provide optimization solutions covering raw material modification, formulation and production operations after receiving technical support requests from the client. After failing to resolve issues with domestic suppliers, the group formally appointed HiSiaddi to rely on our raw material physicochemical technology and end-product formulation database to fully trace failure root causes, optimize raw material indicators and end-product formulation processes in stages, and deliver a systematic rectification plan.
1.
Substandard powder physical properties causing continuous mesh clogging and excessive filling weight deviation on fully automatic soft capsule filling lines The client operates fully enclosed German imported powder direct soft capsule filling equipment with internal control standards requiring raw material D90 particle size ≤20μm, angle of repose 27°±2°, bulk density 0.52–0.56g/cm³, and powder free of electrostatic agglomeration or mixed coarse/fine particles. Generic domestic alpha-lipoic acid adopts conventional hot-air drying + hammer milling processes, producing needle-like crystals with particle size ranging from 45–180μm. Severe electrostatic buildup in fine powder and angle of repose >39° lead to mesh clogging from agglomerates after only 2–3 hours of feeding. Single-capsule filling weight error peaks at 5.2%, far exceeding the brand’s internal pass threshold of ±1.8%. Production lines require frequent shutdowns for mesh disassembly and cleaning, cutting production efficiency by over 55%.
2.
3.
Poor raw material stability leading to rapid oxidative yellowing and severe active ingredient loss in soft capsules under room-temperature storage The disulfide bond within the alpha-lipoic acid molecule renders it highly sensitive to oxygen, temperature and light. The client mandates a 24-month shelf life with active ingredient attenuation ≤4% under room-temperature storage. Uncoated generic raw material powder directly contacts air; semi-finished soft capsules turn pale brown from light yellow after only 42 days of room-temperature storage, with HPLC testing showing a 13.6% drop in active ingredient content – failing quality requirements for French pharmacy shelf placement and risking mass scrapping of stored semi-finished goods.
4.
5.
Layer separation and flocculent precipitation in weakly acidic essence stock solutions during compounding The client’s clinical essence formulation has a pH of 4.2–4.8, compounded with vitamin C, plant flavonoids, hyaluronic acid and other active ingredients. Generic domestic alpha-lipoic acid exhibits drastically reduced solubility in weakly acidic aqueous environments, forming pale yellow flocculent precipitates at the bottom of bottles after 24 hours of standing, failing light transmittance standards for French cosmetic safety inspections and resulting in scrapped small-batch trial essences.
6.
7.
Intrinsic pungent sulfur odor from raw materials released during high-temperature pelleting, contaminating finished goods Generic synthetic alpha-lipoic acid retains trace low-molecular sulfur-containing byproducts. The client’s soft capsule hot-melt pelleting temperature is controlled at 62℃, triggering massive release of irritating sulfur odors upon heating. Opened capsules emit obvious unpleasant odors, failing sensory acceptance standards for premium French dietary products and blocking access to high-end pharmacy sales channels.
8.
9.
Incompatibility with auxiliary materials leading to uncontrolled sustained-release capsule disintegration time limits The client’s sustained-release capsules use calcium hydrogen phosphate and hypromellose as filling and sustained-release skeleton excipients. Trace residual organic solvents and impurities in domestic raw materials trigger micro-complexation reactions with auxiliary materials, extending finished product disintegration time from the standard 45 minutes to over 120 minutes and deviating drug release profiles from pharmacopoeia specifications – failing access requirements for medical dietary products.
10.
Combining the physicochemical properties of alpha-lipoic acid, European finished product formulation systems and the client’s production line operating conditions, HiSiaddi’s technical team split failure causes into three categories: raw material production process defects, unreasonable end-formulation details and three overlooked production workshop control gaps. This avoids one-sided rectification relying solely on formulation adjustments or raw material replacement:
1. Raw material root cause: Domestic manufacturers adopt ambient-temperature crystallization + conventional drying processes without low-temperature airtight crystallization, inert gas-protected milling or surface coating modification workshops. Irregular crystal morphology and incomplete impurity removal form the core drivers of poor powder performance, easy oxidation and strong odor.
2. Formulation root cause: The client’s original European formulations were designed around imported microencapsulated modified raw materials. Direct substitution with uncoated domestic powder without synchronized adjustments to pre-dissolution, feeding sequence and auxiliary material ratios, plus insufficient buffer additives in weakly acidic systems, triggered layered precipitation.
3. Production root cause: Workshop humidity during feeding exceeded 65%, accelerating alpha-lipoic acid moisture absorption and caking. Fully open feeding operations exposed raw materials to air, further amplifying oxidative deterioration of finished goods.
After clarifying failure triggers, HiSiaddi established a three-in-one rectification strategy: targeted raw material fine-tuning + end-formulation optimization + on-site production process improvement. We coordinated manufacturers equipped with GMP pharmaceutical workshops and powder modification capabilities to implement segmented optimization solutions.
1. HiSiaddi collaborated with production manufacturers to adjust crystallization processes with full nitrogen-sealed low-temperature controlled crystallization, optimizing cooling rates to produce nearly spherical crystal particles instead of original needle-shaped crystals.
2. Conventional milling equipment was replaced with liquid nitrogen low-temperature inert jet milling, with graded screening locked at D90=16.8μm. Tested angle of repose reached 26.1°, bulk density 0.54g/cm³, producing loose powder free of electrostatic agglomeration.
3. Trace pharmaceutical-grade silicon dioxide was added as a surface flow aid to improve powder physical properties for automatic filling equipment. Post-optimization samples ran continuously on filling machines for 24 hours without mesh clogging, with capsule filling weight error stably controlled within ±1.2%, fully resolving filling failures.
A low-temperature spray coating process was added to post-treatment workshops, using USP-grade β-cyclodextrin compounded with trace natural vitamin E to form a dense protective film on alpha-lipoic acid crystal surfaces, isolating oxygen and water vapor intrusion and blocking oxidative cleavage of disulfide bonds. Accelerated stability testing (40℃, RH75%) over 6 months recorded active ingredient attenuation of only 2.72%, with no discoloration or browning after 12 months of room-temperature retention samples, satisfying the mandatory 24-month shelf life requirement and eliminating soft capsule yellowing and failure during storage at the raw material source.
1. Formulation adjustment: Guided the client to add 0.3% citric acid-sodium citrate buffer salt to essence systems, locking the buffer range at pH4.3–4.9 to stabilize liquid-phase environments and prevent alpha-lipoic acid precipitation under acidic conditions.
2. Feeding process adjustment: Replaced direct dry powder feeding with pre-dissolution of alpha-lipoic acid in propylene glycol + purified water at a constant 40℃, followed by slow addition to the main essence base under continuous stirring to avoid localized instantaneous over-acid agglomeration. Post-optimization samples remained clear and transparent with zero precipitation after 90 days of standing, with no colloidal flocculation when compounded with vitamin C and plant flavonoids.
1. A two-stage negative-pressure rectification solvent removal process was added to factory refining stages to deeply strip low-molecular sulfur-containing byproducts and organic solvent residues from synthesis, strictly controlling single solvent residuals below 0.5ppm.
2. A low-temperature vacuum deodorization stage was added prior to finished product packaging to strip volatile odor impurities under negative pressure. Optimized raw materials emit no pungent sulfur odors, and no odor release occurred during the client’s 62℃ high-temperature pelleting tests, meeting sensory acceptance standards for French import inspections.
Combining raw material impurity and compatibility data, HiSiaddi guided the client to fine-tune sustained-release formulations: reducing original hypromellose addition by 2.2% and supplementing 0.8% microcrystalline cellulose to adjust skeleton porosity, alongside modified powder pre-mixing sequences. Alpha-lipoic acid was pre-mixed with dry auxiliary materials in airtight low-temperature environments for 30 minutes prior to granulation feeding. Post-adjustment finished goods exhibited stable disintegration times of 42–48 minutes, with drug release profiles complying with European EP Pharmacopoeia standards and passing medical dietary raw material filing testing.
Guided the client to control feeding workshop humidity between 40%–50%, install negative-pressure airtight dust extraction devices at feeding ports, and shorten raw material open-air exposure time to reduce moisture absorption and oxidation during production, further consolidating finished product stability.
1. Sample verification phase: HiSiaddi coordinated manufacturers to produce 15kg optimized trial samples, split into three portions for soft capsule filling testing, essence compounding testing and sustained-release capsule formulation testing respectively. Full physicochemical and finished product testing conducted at the client’s R&D center in Lyon, France passed all indicators in one round, with a written sample qualification confirmation report issued by the French side.
2. Pilot production phase: A 2.8-ton pilot batch of raw materials was produced following optimized processes. HiSiaddi stationed on-site staff to oversee full production sampling, with testing conducted every 500kg at SGS EU-recognized laboratories – all indicators complied with EP Pharmacopoeia and French import standards. Goods were shipped from Shanghai Port to Marseille Port with smooth customs clearance and warehousing, enabling full-load production across three client lines with zero semi-finished product scrapping.
3. Annual framework launch: After zero production failures in pilot batches, the client formally signed an annual procurement framework for 21 tons delivered in six quarterly shipments. HiSiaddi established a batch pre-review mechanism to verify raw material indicators prior to each shipment, alongside preparation of full export compliance documents including English COA, multi-language GHS SDS and free sales certifications.
1. The client fully terminated original procurement of alpha-lipoic acid from Roche (Switzerland), switching entirely to customized modified raw materials manufactured in China. Comprehensive procurement costs decreased by 23%, and lead times were compressed from the original 80 days to 32 days.
2. Building on the success of this formulation optimization project, the client expanded into high-end medical beauty channels in Luxembourg with new demand for high-activity R-configured alpha-lipoic acid, entrusting HiSiaddi’s technical team to fully support early-stage formulation compatibility testing, generating an incremental annual procurement volume of 7.5 tons.
3. During the R&D phase of the client’s new effervescent tablet product line, HiSiaddi was commissioned in advance to conduct raw material selection and formulation pre-adaptation to avoid mass production risks at an early stage.
Most domestic alpha-lipoic acid manufacturers focus on mass production of generic bulk raw materials, specializing solely in synthesis with limited knowledge of end-product formulation, unfamiliar with formulation logic for various dosage forms of European and American mid-to-high-end brands, automatic production line parameters and stringent storage standards for finished goods. Mid-to-high-end European health enterprises develop products spanning soft capsules, sustained-release preparations and medical beauty essences; minor physical and chemical defects in raw materials compounded with formulation compatibility deviations easily trigger full production line shutdowns and massive semi-finished product losses.
Drawing on physicochemical technical reserves for alpha-lipoic acid and end-product formulation databases for European and American markets, HiSiaddi breaks free from the one-sided limitation of raw material manufacturers only optimizing raw materials or formulation factories only adjusting formulas. We implement systematic troubleshooting solutions covering raw material process improvements, end-formulation fine-tuning and workshop production control, resolving client mass production technical challenges comprehensively. Our actionable technical services bind long-term repeat large-volume orders from overseas mid-to-high-end clients, while helping premium domestic fine chemical manufacturers penetrate the high-end customized raw material market in Europe.
Contact HiSiaddi customer service for inquiries about formulation optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
